



Continuation of Substance of Interview including description of the general nature of what was discussed:

The examiner contacted the applicant, discussing potentially allowable subject matter, and remaining issues, with suggestions for claim amendment. The examiner indicated that the amended claims 27, 28 and 30 would be rejected under 35 U.S.C. 112, first paragraph, for lack of enablement and adequate written description. The examiner also indicated rejoinder of group IV invention (claims 4 and 44 in part, and claims 46-50), directed to an IL-15 mutein which is an IL-15 antagonist, and pointed out the remaining issues with these claims. Applicants agreed to file supplemental amendment, amending the claims and canceling other non-elected/withdrawn claims.